SEC62 and ovarian carcinoma: Only if these in vitro experiments demonstrate a causative effect of SEC62 overexpression on these three hallmarks in ovarian cancer cells, future in vivo experiments will address Sec62 as a potential therapeutic target for this tumor entity (also reviewed in this Research Topic by Zimmermann et al., 2022).